Document Detail


Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine.
MedLine Citation:
PMID:  22268377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The aim of this study was to report a single-centre experience of flunarizine in childhood migraine with focus on safety and efficacy.
METHOD: We conducted a retrospective observational audit of 72 individuals (40 male, 32 female; mean age 13y; age range 1y 6mo-17y) at a tertiary paediatric neurology unit between 1998 and 2009. Children were included if they had a diagnosis of migraine and at least one follow-up assessment and a minimum of 3 months' treatment with flunarizine.
RESULTS: Of 102 individuals identified, 30 were excluded for the following reasons: no outcome data (n=13), non-migraineurs (n=9), missing records (n=4), or inadequate treatment duration (n=4). Of the final cohort (72 individuals), 44 had migraine without aura, 15 had migraine with aura or childhood migraine equivalents, eight had sporadic hemiplegic migraine, and five had familial hemiplegic migraine. The median age was 13 years (1y 6mo-17y) and median duration of migraine was 48 months. Starting dose was 5mg. Other doses used were 2.5mg (three individuals), 7.5mg (one individual), and 10mg (six individuals). Treatment duration was 12 months. Successful prophylaxis, defined as at least a 50% reduction in attack frequency, was observed in 57% (41/72). Response rate was higher among those with hemiplegic migraines (85%) than in those who did not have hemiplegic migraines (51%). Side effects were noted in 15 (21%) individuals (depression, n=6; weight gain/increased appetite, n=5; tiredness/sedation, n=2; and worsening headache, n=2), and led to discontinuation of treatment in 13.
INTERPRETATION: In our cohort of children with migraine, flunarizine appears to be more effective in the hemiplegic migraine group. Adverse effects were seen in one-fifth of the individuals, leading to discontinuation in 18%.
Authors:
Basheer Peer Mohamed; Peter J Goadsby; Prab Prabhakar
Related Documents :
15296247 - Section 5(2) of the mental health act: local and national use over a twelve-year period.
20170407 - Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery ...
22057947 - Comparison of three protocols for superovulation of brown brocket deer (mazama gouazoub...
11883347 - Manual removal of the placenta and postcesarean endometritis.
8499507 - Ketorolac and propofol administration for prevention of nausea and vomiting in patients...
7822917 - Initial treatment of closed metacarpal fractures. a controlled comparison of compressio...
Publication Detail:
Type:  Journal Article     Date:  2012-01-23
Journal Detail:
Title:  Developmental medicine and child neurology     Volume:  54     ISSN:  1469-8749     ISO Abbreviation:  Dev Med Child Neurol     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-13     Completed Date:  2012-03-27     Revised Date:  2012-07-13    
Medline Journal Info:
Nlm Unique ID:  0006761     Medline TA:  Dev Med Child Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  274-7     Citation Subset:  IM    
Copyright Information:
© The Authors. Developmental Medicine & Child Neurology © 2012 Mac Keith Press.
Affiliation:
Children's Headache Clinic, Great Ormond Street Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Child, Preschool
Drug Toxicity*
Female
Flunarizine / adverse effects,  therapeutic use*
Humans
Infant
Longitudinal Studies
Male
Migraine with Aura / drug therapy*
Pediatrics*
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Vasodilator Agents / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 52468-60-7/Flunarizine
Comments/Corrections
Comment In:
Dev Med Child Neurol. 2012 Mar;54(3):204-5   [PMID:  22142366 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Twelve-year Incidence of Exfoliation Syndrome in the Reykjavik Eye Study.
Next Document:  Vibrio azureus emits blue-shifted light via an accessory blue fluorescent protein.